Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Grigg

Showing results (161-170 of 180) with videos related to

Pageof 18
Sort By:
British Journal of Haematology|June 1, 1997
Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDFJ E Rasko, R L Basser, J Boyd, et al.
Blood|May 1, 1997
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.
Leukemia|July 31, 2009
The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemiaK D Mason, S L Khaw, K C Rayeroux, et al.
Haematologica|October 5, 2023
Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1Howland E Crosswell, Ann S LaCasce, Nancy L Bartlett, et al.
Ebiomedicine|June 29, 2021
Oral administration of maternal vaginal microbes at birth to restore gut microbiome development in infants born by caesarean section: A pilot randomised placebo-controlled trialBrooke C Wilson, Éadaoin M Butler, Celia P Grigg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2022
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration CohortsPaul M Barr, Alessandra Tedeschi, William G Wierda, et al.
Blood|November 1, 1996
Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activationC J O'Malley, J E Rasko, R L Basser, et al.
Pathology|March 6, 2021
Myeloid somatic mutation panel testing in myeloproliferative neoplasmsDavid M Ross, Candice Thomson, Nada Hamad, et al.
The New England Journal of Medicine|July 8, 2005
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemiaClaire N Harrison, Peter J Campbell, Georgina Buck, et al.
Leukemia|September 3, 2010
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCRD M Ross, S Branford, J F Seymour, et al.
Pageof 18

Showing results (161-170 of 180) with videos related to

Sort By:
Pageof 18
British Journal of Haematology|June 1, 1997
Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDFJ E Rasko, R L Basser, J Boyd, et al.
Blood|May 1, 1997
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.
Leukemia|July 31, 2009
The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemiaK D Mason, S L Khaw, K C Rayeroux, et al.
Haematologica|October 5, 2023
Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1Howland E Crosswell, Ann S LaCasce, Nancy L Bartlett, et al.
Ebiomedicine|June 29, 2021
Oral administration of maternal vaginal microbes at birth to restore gut microbiome development in infants born by caesarean section: A pilot randomised placebo-controlled trialBrooke C Wilson, Éadaoin M Butler, Celia P Grigg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2022
Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration CohortsPaul M Barr, Alessandra Tedeschi, William G Wierda, et al.
Blood|November 1, 1996
Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activationC J O'Malley, J E Rasko, R L Basser, et al.
Pathology|March 6, 2021
Myeloid somatic mutation panel testing in myeloproliferative neoplasmsDavid M Ross, Candice Thomson, Nada Hamad, et al.
The New England Journal of Medicine|July 8, 2005
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemiaClaire N Harrison, Peter J Campbell, Georgina Buck, et al.
Leukemia|September 3, 2010
Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCRD M Ross, S Branford, J F Seymour, et al.
Pageof 18